Breakpoint Therapeutics
12:15 PM - 12:30 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104A
Breakpoint Therapeutics GmbH is a pre-clinical stage company dedicated to the discovery and development of novel oncology drugs that target the DNA damage response (DDR) in cancer cells.
Currently, we prosecute two next-generation oncology targets: DNA Polymerase Theta (PolQ) and Werner Helicase (WRN).
Breakpoint was founded in 2019 as a spin-off from Evotec and backed by a €30 million series A that was extended in 2021. Our investors are Medicxi, Taiho Ventures, Evotec and BVF Partners.
Currently, we prosecute two next-generation oncology targets: DNA Polymerase Theta (PolQ) and Werner Helicase (WRN).
Breakpoint was founded in 2019 as a spin-off from Evotec and backed by a €30 million series A that was extended in 2021. Our investors are Medicxi, Taiho Ventures, Evotec and BVF Partners.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Hamburg
Company HQ Country:
Germany
Year Founded:
2019
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Inhibitor of Polymerase Theta (PolQ);
Inhibitor of Werner Helicase (WRN)
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
